Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa in heart failure with anemia (double-blind, randomized, placebo-controlled, multicenter)
2005-005278-59Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2006
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF), left ventricular systolic dysfunction (LVSD) and anaemia comparing Darbepoetin alfa with Placebo (2 arms). Primary endpoint: Time to death from any cause or first hospital admission for worsening heart failure. Started Apr 2006; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)anaemia
Beyond the preview
Go deeper on 2005-005278-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005278-59.